Jeeva Clinical Trials Inc.’s Post

Caitlin Moore, VMD, DACVIM-LAIM, Adnan Patel, Albert Whangbo and Christina Corridon's analysis sheds light on the decision-making process of oncologists regarding therapy choices: - Most physicians consider two to three therapies, with a small portion (10%) exploring more than three options. - Onco-generalists tend to choose chemotherapy more frequently, leaning towards a standardized approach due to the wide variety of tumor types they manage - likely due to their ease of reimbursement and alignment with institutional protocols etc. - This contrasts with specialists, who explore a broader range of therapies, reflecting their deep expertise and provides challenges to them considering increase in the number and type of choices (e.g., new modalities, complex science)

That's a wrap for #ecdp2024! We, Roche team greatly appreciate the conversations with #Pathologist #clinician #computerscientist and #pathology #ai industry and academia partners to work together to support #digitalpathology in the #patientjourney. 3 thoughts from my own personal perspective: 1) How and when academia brilliance in the field of AI federated learnings will translte into the clinical adoption? 2) How closely precision medicine development will help to close the market access gap? 3) Open API is the key going forward for healthy partnerships. Kristīne Soboļevska Luke Benko Marta Canamero Javier Medina Bellver Santiago Morillo Joost van Duuren Thomas Plagge Antonio Teruel Luceno Claire F. Norman Zerbe Michael Rivers Shruti Mathur Ravi Chana Daniel Plews Chris Hudson Ashton Harper, MD Oswaldo Rodriguez Katalin Érsek Ernest Lo Thomas Plagge Tomas Andriekus Gunita Varblane navify®Roche Diagnostics UK & Ireland Roche Lietuva Roche LATAM Roche Germany Roche Diagnostics España

ICCS recognizes the importance of TRBC testing for T-cell neoplasms. Beckman Coulter Life Sciences has developed a TRBC2 antibody for use in #flowcytometry for scientists to be able to run both TRBC1 and 2 for a full picture. Check your this article to learn more about it: Beckman Coulter Launches Groundbreaking Anti-TRBC2 Conjugated Antibody for Flow Cytometry https://lnkd.in/g_n-YY2u

We're intrigued by a recent paper on a promising new use case for #syntheticdata in clinical trials. While still very preliminary, an Italian team led by Matteo G Della Porta showed the potential for creating “synthetic patients” as a control group for clinical trials - making such trials much more cost-effective and quicker to run. ✅ Researchers used real patient data to train a model to generate a “mirror cohort” of synthetic records of patients with the blood disease myelodysplastic syndrome (MDS). ❇️ They've developed an associated tool that allows those working on MDS to generate cohorts of up to 10,000 synthetic patients, complete with clinical, genomic, and follow-up data. ⭐️ Della Porta says that that’s a potential game-changer for research on disorders for which “very few data are publicly available.” Obviously we have to proceed carefully here, but this is a very encouraging sign for ways that synthetic data can be used that can concretely help with further research and development of new medical treatments. PNAS overview: https://lnkd.in/ew5pM-Ca Paper: https://lnkd.in/eNZaJRPQ #clinicaldata #researchdata #syntheticdata #healthcaredata

Among the many interesting discussions at #LATSS2024, the commercial challenges in rare diseases continues to confront the field.

Research and Development is moving at such a pace that what was once unthinkable - a cure for Type 1 diabetes - now feels well within reach. Great work from Professor Hebrok and the team and full speed ahead to Diabetes UK on the #Type1DiabetesGrandChallenge

Unlock the future of disease research with 3D cell models. These innovative organoids are breaking down traditional barriers, offering a more accurate representation of human tissue than ever before. From creating disease models to testing new drugs, they're paving the way for personalized medicine. Learn more about two techniques used to generate insight into biological processes utilizing advanced cell models: https://ow.ly/uPEH50Q8TvM #3DCellModels #DiseaseResearch #PersonalizedMedicine

Are #flashbackfridays still a thing? Seems timely to have this "making cells talk" article pop up from my Beth Israel Deaconess Medical Center days with Vasilis Toxavidis & John Tigges! Now instead of making cells talk, I spend my days helping people listen to what their cells are saying. 😉 What secrets are YOUR cells looking to share? #flowcytometry #nocellsleftbehind #singlecellanalysis #multiomics #scRNAseq #transcriptomics

Unlock the future of disease research with 3D cell models. These innovative organoids are breaking down traditional barriers, offering a more accurate representation of human tissue than ever before. From creating disease models to testing new drugs, they're paving the way for personalized medicine. Learn more about two techniques used to generate insight into biological processes utilizing advanced cell models: https://ow.ly/GYk250Q8TnU #3DCellModels #DiseaseResearch #PersonalizedMedicine

Learn in this brand new article how Matthew R. Lewis describes the Benefits of 4D-Lipidomics and how it brings research to the Clinic https://lnkd.in/e-dTB4-a